4.7 Review

Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease

Journal

CELL STEM CELL
Volume 10, Issue 3, Pages 244-258

Publisher

CELL PRESS
DOI: 10.1016/j.stem.2012.02.005

Keywords

-

Funding

  1. Indo US Science and Technology Forum (IUSSTF)
  2. JNCASR
  3. Sanofi
  4. National Institute of Health [HL097172, HL095722]

Ask authors/readers for more resources

The broad repertoire of secreted trophic and immunomodulatory cytokines produced by mesenchymal stem cells (MSCs), generally referred to as the MSC secretome, has considerable potential for the treatment of cardiovascular disease. However, harnessing this MSC secretome for meaningful therapeutic outcomes is challenging due to the limited control of cytokine production following their transplantation. This review outlines the current understanding of the MSC secretome as a therapeutic for treatment of ischemic heart disease. We discuss ongoing investigative directions aimed at improving cellular activity and characterizing the secretome and its regulation in greater detail. Finally, we provide insights on and perspectives for future development of the MSC secretome as a therapeutic tool.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available